Multiple Sclerosis Clinical Trials in Los Angeles

Showing 101-120 of 269 trials

A Study of LY3022855 In Participants With Breast or Prostate Cancer

NCT02265536

The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).

NeoplasmsNeoplasm Metastasis

Eli Lilly and Company34 participantsStarted May 2015

Los Angeles, California, United States • New York, New York, United States

COMPLETEDNA< 1 mile

The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation

NCT03640325

Multisite Randomized Controlled Trial (RCT) testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults receiving hematopoietic cell transplantation for hematology malignancy.

CancerBone Marrow NeoplasmsAnxiety+5 more

Seattle Children's Hospital143 participantsStarted Apr 2019

Birmingham, Alabama, United States • Los Angeles, California, United States • Boston, Massachusetts, United States +2 more locations

ACTIVE_NOT_RECRUITING< 1 mile

Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients

NCT03757182

The purpose of this study is to examine the relationships between objectively measured physical activity and provider-assessed and patient-reported functional outcomes in patients with advanced cancer. Findings from this study will help us better understand how change in daily physical activity, as measured using the wearable activity monitor, is related to change in a patient's functional status and clinical condition.

CancerCancer, MetastaticNeoplasms

Cedars-Sinai Medical Center80 participantsStarted Dec 2018

Los Angeles, California, United States

A Study of LY3022855 In Participants With Breast or Prostate Cancer

The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation

Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients

Multiple Sclerosis Trials in Other Cities

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Safety and Effectiveness Study of the Zenflow Spring System

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Tracking Renal Tumors After Cryoablation Evaluation

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Other Conditions in Los Angeles